“Does this patient have…” “Is this patient at risk for infection with multidrug resistant bacteria?”

Intensive Care Medicine

Volumn 43, Issue 3, 2017, Pages 436-439

  Guillamet, Cristina Vazquez ^a   Kollef, Marin H ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEMASE; ANTIINFECTIVE AGENT;

ACINETOBACTER; AGED; ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CASE REPORT; CRITICALLY ILL PATIENT; EDITORIAL; END STAGE RENAL DISEASE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFECTION RISK; INSULIN DEPENDENT DIABETES MELLITUS; KLEBSIELLA PNEUMONIAE; LOBAR PNEUMONIA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; OUTPATIENT CARE; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; RISK; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANTIMICROBIAL STEWARDSHIP; COMPLICATION; CRITICAL ILLNESS; CROSS INFECTION; DECISION MAKING; INTENSIVE CARE UNIT; PNEUMONIA; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL STEWARDSHIP; CRITICAL ILLNESS; CROSS INFECTION; DECISION MAKING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA; RISK FACTORS;

EID: 84946761377     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-4126-1     Document Type: Editorial

References (17)

1. Maragakis LL, Perencevich EN, Cosgrove SE (2008) Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 6:751–763. doi:10.1586/14787210.6.5.751
2. Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474
3. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637. doi:10.1097/CCM.0b013e31827e83af
4. Kollef MH, Micek ST (2012) Antimicrobial stewardship programs: mandatory for all ICUs. Crit Care 16:179. doi:10.1186/cc11853
5. Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E, Kalil AC (2014) Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 58:5262–5268. doi:10.1128/AAC.02582-14
6. American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416
7. Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, Micek ST, Kollef MH (2012) Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 54:193–198. doi:10.1093/cid/cir813
8. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, Tarsia P, Mantero M, Blasi F (2012) Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 54:470–478. doi:10.1093/cid/cir840
9. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, Yuda H, Yoshida M, Kobayashi H, Taguchi O, Gabazza EC, Takei Y, Miyashita N, Ihara T, Brito V, Niederman MS (2013) A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug resistant pathogens to select initial empiric therapy. Clin Infect Dis 57:1373–1383. doi:10.1093/cid/cit571
10. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y (2013) Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188:985–995. doi:10.1164/rccm.201301-0079OC
11. Falcone M, Russo A, Giannella M, Cangemi R, Scarpellini MG, Bertazzoni G, Alarcón JM, Taliani G, Palange P, Farcomeni A, Vestri A, Bouza E, Violi F, Venditti M (2015) Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia. PLoS ONE 10(4):e0119528. doi:10.1371/journal.pone.0119528 (eCollection 2015)
12. Vallés J, Martin-Loeches I, Torres A, Diaz E, Seijas I, López MJ, Garro P, Castillo C, Garnacho-Montero J, Martin Mdel M, de la Torre MV, Olaechea P, Cilloniz C, Almirall J, García F, Jiménez R, Seoane E, Soriano C, Mesalles E, Posada P (2014) Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med 40(4):572–581. doi:10.1007/s00134-014-3239-2
13. Self WH, Wunderink RG, Williams DJ, Barrett TW, Baughman AH, Grijalva CG (2015) Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia. Acad Emerg Med 22:730–740. doi:10.1111/acem.12672
14. Chalmers JD, Rother C, Salih W, Ewig S (2014) Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 58:330–339. doi:10.1093/cid/cit734
15. Garcia-Vidal C, Viasus D, Roset A, Adamuz J, Verdaguer R, Dorca J, Gudiol F, Carratalà J (2011) Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol Infect 17:1659–1665. doi:10.1111/j.1469-0691.2011.03484.x
16. Sibila O, Laserna E, Maselli DJ, Fernandez JF, Mortensen EM, Anzueto A, Waterer G, Restrepo MI (2015) Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia. Respirology 20(4):660–666. doi:10.1111/resp.12506 (Epub 2015 Mar 16)
17. Kollef MH (2014) What can be expected from antimicrobial de-escalation in the critically ill? Intensive Care Med 40:92–95. doi:10.1007/s00134-013-3154-y